newsfilter
← Latest News
GlobeNewswire·

ArriVent BioPharma Reports Second Quarter 2025 Financial Results

Positive interim Phase 1b update underscores firmonertinib's potential in EGFR PACC mutant NSCLC; global pivotal Phase 3 ALPACCA study expected to enroll first patient in 2H 2025Dosed the first patient in the Phase 1